DUBLIN--(BUSINESS WIRE)--The "Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture, Type of Media, Scale of Operation, Type of End-User, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine.
In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.
Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing.
The recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.
Companies Mentioned
- 2BScientific
- Adimmune
- Aduro Biotech
- Advagene Biopharma
- Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
- Advanced BioScience Laboratories
- Advent
- AJ Biologics
- Albany Molecular Research
- Alopexx Vaccine
- Altimmune
- Amphera
- Anhui Zhifei Longcom Biologic Pharmacy
- Applied Biosystems
- Argos Therapeutics
- Astellas Pharma
- Asterias Biotherapeutics
- ATZ labs
- Auro Vaccines
- Aurora Biopharma
- AVAX Technologies
- Avid Bioservices
- AVIR Green Hills Biotechnology
- Batavia Biosciences
- Bavarian Nordic
- BD Biosciences
- Beijing Minhai Biotechnology
- Beijing Zhifei Lvzhu Biopharmaceutical
- Bharat Biotech
- Bielefeld University
- Bio Farma
- BioCell
- BioConnection
- Biofabri
- Biological E
- Biological Industries
- BioMARC
- BioReliance
- BlueWillow Biologics
- Boehringer Ingelheim
- Boryung Pharmaceutical
- BravoVax
- Bryllan
- CanSino Biologics
- Capricorn Scientific
- Catalent Biologics
- Cellca (Acquired by Sartorius)
- CellGenix
- CEVEC Pharmaceuticals
- Charles River Laboratories
- Chengdu Zenmindes Biotechnology
- CiMaas
- CJ HealthCare
- Cobra Biologics
- Codagenix
- Commonwealth Serum Laboratories (CSL)
- Creative Biolabs
- Curevo Vaccine
- Cytiva
- CyTuVax
- And Many More Companies!
Key Questions Answered
- Who are the key players engaged in the development of viral vaccine cell culture media?
- Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
- What type of partnership models are commonly adopted by stakeholders engaged in this industry?
- What is the relative competitiveness of different viral vaccine cell culture media?
- Who are the most likely partners for vaccine cell culture media developers?
- What are the key challenges currently faced by stakeholders in this industry?
- What are the anticipated future trends related to viral vaccine cell culture media developers?
- How is the current and future market opportunity likely to be distributed across key market segments?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY PROFILES
6. RECENT DEVELOPMENTS AND INITIATIVES
7. LIKELY PARTNER ANALYSIS
8. PRODUCT COMPETITIVENESS ANALYSIS
9. BRAND POSITIONING
10. PATENT ANALYSIS
11. DEMAND ANALYSIS
12. MARKET FORECAST
13. CONCLUSION
14. INTERVIEW TRANSCRIPT(S)
15. APPENDIX I: TABULATED DATA
16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/t9dhox
